This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
Development PipelineSGN-ALPV
a novel, investigational antibody–drug conjugate directed to ALPP and/or ALPPL2
The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Clinical Trials
SGNALPV-001: Advanced solid tumors
-
Phase 1
-
Phase 2
-
Phase 3
Program Resources

High-level synopsis of SGN-ALPV and ongoing clinical trials

Detailed information about SGN-ALPV clinical trials
Related Links